CJC-1295 with DAC
GHRH analog
Also known as: CJC-1295 DAC, DAC:GRF, Drug Affinity Complex GRF
Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.
Estimated 5.8-8.1 days (139-194 h) in healthy adults after subcutaneous dosing. The long duration comes from covalent binding to serum albumin via the DAC maleimide linker. Single doses raised mean plasma GH 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9-11 days.
No absolute mcg dose is established. The published trial dosed by body weight: 30 and 60 mcg/kg subcutaneously, weekly or biweekly. Absolute values are left blank rather than back-calculated from an assumed body weight. Commonly cited fixed doses (1-2 mg/week) are community convention with no published basis.
Phase 1/2 trials reported no serious adverse reactions across 28- and 49-day studies. Long-term safety is entirely uncharacterised. Sustained non-pulsatile elevation of GH/IGF-1 raises theoretical concern for insulin resistance, oedema, arthralgia, carpal tunnel syndrome, and promotion of occult malignancy, these are class effects documented for GH/GHRH agents rather than measured CJC-1295 outcomes.